This week in therapeutics




Licensing status

Publication and contact ­information

Cardiovascular disease

Myocardial infarction (MI); ischemia/reperfusion injury

MicroRNA-199a-3p (miR-199a-3p); miR-590-3p

Rodent studies suggest exogenous human miR-590-3p and miR-199a-3p could help promote cardiac repair following MI. In rat cardiomyocytes, vector-induced expression of human miR-590-3p or miR-199a-3p both increased proliferation compared with expression of control miRNA. In a mouse model of MI, viral vector-induced expression of miR-590-3p or miR-199a-3p decreased infarct size and increased cardiac function compared with expression of control miRNA. Next steps include developing a pharmaceutical formulation of the miRNAs, assessing the best route of delivery and evaluating efficacy in larger animal models.

SciBX 5(49); doi:10.1038/scibx.2012.1281
Published online Dec. 20, 2012

Patent pending covering use of miRNAs for inducing cardiomyocyte proliferation for use in cardiovascular indications; available for licensing

Eulalio, A. et al. Nature; published online Dec. 5, 2012;
Contact: Mauro Giacca, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy